Evommune, Inc.

Stage 4 · Declining · week 9

As of Oct 22, 2026, Evommune is in Stage 4, the downtrend phase, now in week 9 (since Aug 25, 2026). It closed at $5.21, below its 200-day average, which is falling.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. More about the company

$5.21

+0.77% today

$189M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is EVMN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-11-06 → 2026-10-22

S? 42w

S4 8w

2025-11-062026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 8w current

Total tracked: 50 weeks across 2 stage runs.

EVMN among Biotechnology564th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…564	EVMNEvommune, Inc.	Stage 4 · wk 9	—	−40.6%

vs 52W High

—

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 9

1w13w26w

Week 9, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-71.3%

200 DMA: $18.17 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.36x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-40.6%

-54.1%

-79.8%

YTD

-69.9%

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 9 · Vol 0.36x

2026-10-21S4

Wk 9 · Vol 0.53x

2026-10-20S4

Wk 8 · Vol 0.53x

2026-10-19S4

Wk 8 · Vol 0.59x

2026-10-16S4

Wk 8 · Vol 1.38x

2026-10-15S4

Wk 8 · Vol 0.81x

2026-10-14S4

Wk 8 · Vol 0.80x

2026-10-13S4

Wk 7 · Vol 1.11x

2026-10-12S4

Wk 7 · Vol 0.53x

2026-10-09S4

Wk 7 · Vol 0.78x

2026-10-08S4

Wk 7 · Vol 0.97x

2026-10-07S4

Wk 7 · Vol 3.09x

Moving averages & range

50 DMA

$9.80

200 DMA

$18.17

52W High

—

52W Low

—

5D Low

$5.17

Resistance levels (recent highs)

20d High

$8.49

60d High

$15.01

120d High

$25.18

250d High

—

Next resistance

+63.0%

to 20d High

ROE

-52.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

Evommune: quick answers

What stage is Evommune in?

As of Oct 22, 2026, Evommune (EVMN) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 25, 2026 and is in week 9. What the four stages mean

Is Evommune in an uptrend?

No. Evommune is in a Stage 4 downtrend. It trades 71.3% below its 200-day average, which is falling.

How has Evommune performed over the past year?

As of Oct 22, 2026, Evommune is down 69.9% so far in 2026.

Which sector and industry is Evommune in?

Evommune is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.